Core Viewpoint - Bavarian Nordic A/S has submitted clinical data to the European Medicines Agency (EMA) to extend the indication of the MVA-BN mpox and smallpox vaccine to include children aged 2 to 11 years, demonstrating a comparable safety profile and non-inferior immune response compared to adults [1][2]. Group 1: Clinical Study Results - The submission is based on positive topline results from a Phase 2 clinical study involving 227 children aged 2-11 years and 224 adults, showing non-inferiority of immune responses and a similar safety profile between both age groups after vaccination with two standard doses of the MVA-BN vaccine [2]. - The study was co-funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and conducted in the Democratic Republic of Congo and Uganda, where cases of mpox were reported during recent outbreaks [2]. Group 2: Implications and Statements - The potential extension of the Marketing Authorisation for MVA-BN to include individuals from 2 years of age could occur later in 2026 following EMA's review of the data [3]. - The President and CEO of Bavarian Nordic emphasized the importance of broadening vaccine access for children, who are disproportionately affected by mpox, especially in the context of ongoing health challenges [4]. - CEPI's Mpox Disease Programme Lead highlighted that children face a higher risk of severe disease during outbreaks, underscoring the need for expanded vaccine access for this vulnerable population [4]. Group 3: Vaccine Information - MVA-BN is the only non-replicating mpox vaccine approved in several countries, including the U.S., Switzerland, and the EU, originally developed as a smallpox vaccine to ensure supply for the entire population, including immunocompromised individuals [5]. - The vaccine is indicated for use in the general population from 12 years old for those considered at risk for smallpox or mpox infection [5]. Group 4: Company Overview - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines and is a preferred supplier of mpox and smallpox vaccines to governments [6].

Financial Data and Key Metrics Changes - Total revenues exceeded EUR 170 million, slightly above 2024 levels, with almost EUR 160 million in product sales [4] - Operating cash burn reduced by over 20%, driven by disciplined cash management [5] - Loss for the period reached EUR 115.2 million, with an adjusted EBITDA reported at -EUR 51.4 million [20] Business Line Data and Key Metrics Changes - Total product sales reached EUR 157.9 million, decreasing by 3.3% over 2024, primarily due to planned reduction in third-party sales [15] - IXIARO sales grew to EUR 98.4 million, representing a growth of 4.6% [15] - IXCHIQ sales increased to EUR 8.4 million from EUR 3.7 million in the prior year [16] Market Data and Key Metrics Changes - Proprietary product sales, excluding currency effects, grew by 9% year-over-year [15] - Third-party sales decreased significantly from EUR 33.2 million to EUR 19.2 million due to the termination of distribution contracts [16] Company Strategy and Development Direction - The company aims to become a leading vaccine biotech company by growing its commercial business and optimizing cash generation [6] - Plans to enhance the R&D pipeline with a focus on vector-borne diseases and expanding beyond this area [23] - Strategic in-licensing to augment the pipeline and create a risk-balanced portfolio of innovative vaccine assets [23] Management's Comments on Operating Environment and Future Outlook - Management highlighted resilience in a year marked by geopolitical uncertainty and rising vaccine hesitancy [4] - Positive phase 3 results for the Lyme disease vaccine candidate could be transformational, delivering substantial revenue [22] - The company expects total product sales in 2026 to be between EUR 145 million and EUR 160 million, with a focus on reducing operating cash burn [20] Other Important Information - The company closed the year with a cash position of nearly EUR 110 million and enhanced financial flexibility through successful debt refinancing [4] - The Lyme disease vaccine candidate, VLA15, is currently in a pivotal phase 3 study with results expected in the first half of 2026 [6][9] Q&A Session Summary Question: What is the expected timeline for the Lyme data readout? - Management indicated that Pfizer controls the study execution and expects data around mid of H1 2026 [27] Question: What gives confidence in VLA15's efficacy across different serotypes? - Management noted preclinical models showed promising results, but human data is still needed to confirm efficacy across serotypes [30] Question: How will capital allocation change if Lyme is successful? - Management stated that positive phase 3 data would not yield immediate milestones, with commercial sales milestones expected later [34] Question: What is the status of the DoD contract for IXIARO? - Management confirmed that a new contract is expected this year, and current shipments continue under the existing contract [46][58] Question: What are the next steps for the chikungunya vaccine VLA1553? - Management expects approval from Anvisa soon and is evaluating commercialization strategies in Asia [62][64]

Core Viewpoint - The first severe case of the virus has been detected in New York, indicating a potential escalation in the public health crisis and its implications for the healthcare industry and related sectors [1] Group 1 - The detection of the severe case may lead to increased demand for healthcare services and resources in New York [1] - This event could trigger a response from local and state health authorities, impacting public health policies and funding [1] - The healthcare industry may experience heightened scrutiny and pressure to manage the outbreak effectively [1]

Market Overview - U.S. equity markets are experiencing volatility due to disappointing corporate guidance, geopolitical tensions, and mixed economic data affecting interest rate outlooks [1][3] - Major indexes have softened after a strong performance led by technology gains, with the Dow Jones Industrial Average down 121 points (0.24%) to 49,542, S&P 500 down 13 points (0.19%) to 6,868, and Nasdaq Composite down 43 points (0.18%) to 22,712 [2] Economic Data - The Philadelphia Fed Manufacturing Index rose to 16.3 in February, significantly above the consensus estimate of 7.7, indicating continued expansion in regional manufacturing [4] - Initial jobless claims fell more than expected, highlighting the strength of the U.S. labor market [4] - Federal Reserve officials remain cautious about cutting interest rates too soon, with some suggesting potential rate hikes if inflation persists [5] Corporate News - Walmart reported better-than-expected quarterly earnings but issued a cautious profit forecast for 2026, leading to a more than 3% drop in shares [6] - Nvidia is in focus due to a partnership with Meta Platforms for AI chips, although its stock has moderated ahead of its earnings report [7] - Robinhood Markets shares fell 11% after revenue missed forecasts and high expense outlooks were provided [8] - Moderna's stock rose 6% following FDA review news for its flu vaccine candidate [8] - Exxon Mobil shares increased by 2.9% as crude oil prices rose amid geopolitical tensions [8] - Carvana's stock plummeted over 20% after reporting significant profitability loss in Q4 [8] - Smurfit Westrock shares surged 12% after an encouraging five-year financial forecast despite an earnings miss [8] Upcoming Events - Investors are monitoring "Fedspeak" from officials for monetary policy clues, with a primary focus on the upcoming PCE inflation data [9] - Geopolitical developments in the Middle East are influencing oil prices and the global inflation outlook [9]

Market Overview - The US markets are experiencing a mixed performance, with the Dow down approximately 80 points, the S&P 500 down by 0.1%, and the NASDAQ down by about 0.3% [1] - Over the past week, the Dow and S&P 500 have both decreased by 1.5%, while the NASDAQ has fallen by more than 2% [1] - The market remains sensitive to AI-related threats to existing businesses, leading to increased selling pressure, particularly in the tech sector [1] Inflation and Consumer Behavior - The latest Consumer Price Index (CPI) report indicates inflation is rising less than expected, with food prices increasing by 2.9% in January, which is significantly higher than overall price increases [1][2] - A survey reveals that 62% of shoppers prioritize price over brand when making purchasing decisions, reflecting a strong focus on value among consumers [1][2] - The middle and lower-income consumers are reported to be stable but are stretching their budgets and being cautious with discretionary spending [1][2] Retail and Consumer Goods - Retailers perceived as offering higher value, such as Dollar General and Walmart, are seeing increased foot traffic as consumers seek price competitiveness [2] - Promotions are becoming a key strategy for brands to recapture market share, with 68% of new products being discovered through promotions [2] - A notable shift in shopping behavior is observed, with 32% of shoppers making spontaneous decisions based on price and promotions rather than sticking to a pre-made list [2] Energy Sector and Grid Resilience - The North American Electric Reliability Corporation (NERC) reports that tens of millions of people live in areas with a high risk of electricity shortfalls, highlighting the need for significant investment in the power grid [3] - The increasing demand for reliable power is driven by the electrification of various sectors, including manufacturing and data centers, necessitating upgrades to the existing grid infrastructure [3] - Companies like American Superconductor are focusing on providing solutions to enhance power quality and reliability for industrial consumers [3] Corporate Developments - Rivian's shares surged after reporting better-than-expected fourth-quarter results and achieving its first annual gross profit, with expectations for the delivery of its R2 midsize SUV in the second quarter [4] - Pinterest's stock fell to its lowest level since 2020 following a weaker-than-expected first-quarter forecast, prompting multiple analyst downgrades [4] - Moderna reported fourth-quarter revenue that exceeded Wall Street expectations, but faces challenges with the FDA regarding its mRNA flu vaccine [4] Regulatory Changes - President Trump is considering narrowing the scope of steel and aluminum tariffs, which could lower prices for various goods, reflecting ongoing affordability concerns [5] - The Trump administration is repealing the Obama-era endangerment finding related to greenhouse gas regulation, which could significantly impact the auto industry and environmental regulations [5]

Company Overview - Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases, addressing unmet medical needs [6] - The company has a strong track record of advancing multiple vaccines from early R&D to approvals and currently markets three proprietary travel vaccines [6] - Valneva's vaccine pipeline includes candidates for Lyme disease, Zika virus, and other global public health threats, with revenues from its commercial business supporting ongoing development [6] Chikungunya Vaccine Update - The UK’s Commission on Human Medicines (CHM) has updated its recommendations for Valneva's single-dose chikungunya vaccine, IXCHIQ, following a review of its benefits and risks [1] - The updated prescribing information includes restrictions for individuals over 60 years of age and those with specified health conditions, as well as guidelines on vaccination timing prior to travel [2] - The benefit-risk profile of IXCHIQ remains favorable for individuals aged 18 to 59 years who are at risk of chikungunya infection without contraindicated medical conditions [2][3] Safety Monitoring and Regulatory Actions - The update follows a temporary suspension of IXCHIQ's use in older individuals due to reports of serious adverse events primarily among elderly patients with significant underlying health conditions during a vaccination campaign [3] - Valneva is committed to maintaining high safety standards and will continue to monitor post-marketing safety data for IXCHIQ, collaborating with relevant authorities for potential updates to recommendations [4] Chikungunya Virus Context - Chikungunya virus (CHIKV) is a mosquito-borne disease causing severe joint pain, fever, and other symptoms, with significant global outbreaks since 2004 [5] - Over 3.7 million cases were reported in the Americas between 2013 and 2023, with the economic impact considered substantial, expected to grow due to climate change affecting mosquito distribution [5] - The World Health Organization (WHO) has identified chikungunya as a major public health problem, highlighting the need for effective vaccine solutions [5]

Group 1 - The city has launched a program for free HPV vaccination for girls aged 13 and above, specifically targeting those born after November 10, 2011 [1] - Eligible girls can receive two doses of the bivalent HPV vaccine, with a recommended interval of 6 months between doses [1] - Vaccination can be arranged through schools or by contacting local health services via various platforms [1] Group 2 - Starting from November 10, 2025, the HPV vaccine will be included in the national immunization program, expanding access beyond the current local initiatives [2] - For girls entering the first year of junior high school in September 2025, those who have received the first dose under the local initiative can continue with the same vaccine to complete their vaccination [2] - Girls who have not received the local initiative vaccine but meet the national immunization criteria can opt for the national program HPV vaccine [2]

Market Overview - The U.S. stock market closed on December 25, 2025, for Christmas, following a week where major indices reached all-time highs, with normal trading resuming on December 26, 2025 [1] - On Christmas Eve, the S&P 500 rose 0.3% to close at 6,932.05, marking a year-to-date increase of over 17%, while the Dow Jones Industrial Average climbed 0.6% to 48,731.16, and the Nasdaq Composite edged up 0.2% to 23,613.31, contributing to a 21.6% year-to-date advance [3] Futures and Premarket Activity - Futures contracts for major indices were down approximately 0.1% on December 24, 2025, despite a positive sentiment indicated by a slight gain of 0.09% in the US500 index on December 25, reaching 6,938 points [2] Economic Outlook - Key economic indicators to watch include the Federal Reserve Bank of New York's Staff Nowcast on December 26, followed by reports on international trade, pending home sales, and manufacturing surveys on December 29 [4] - The Federal Reserve recently trimmed its benchmark interest rate to a range of 3.5%-3.75%, with analysts expecting rates to remain steady at the January meeting due to mixed economic data [5] Corporate Highlights - Dynavax Technologies saw a 38.2% surge in shares following Sanofi's announcement of a $2.2 billion acquisition [6] - Nike's stock rose 4.6% after Apple CEO Tim Cook purchased nearly $3 million worth of Nike shares [6] - Nvidia shares dipped 0.3% on Christmas Eve but have a year-to-date return of 30.2%, briefly surpassing a $5 trillion market cap in October [10] - Microsoft achieved a 15.6% gain in 2025, with shares trading near $485, leveraging its partnership with OpenAI [10] - ServiceNow confirmed a $7.75 billion acquisition of Armis, although its stock experienced an 11.5% pullback recently [10] - Caterpillar Inc. saw over 60% growth in 2025, driven by its Energy & Transportation segment [10] - Goldman Sachs shares increased by 61% in 2025, identifying potential buying opportunities in the tech sector for 2026 [10] - Eli Lilly shares climbed 40% this year, while Novo Nordisk shares fell nearly 40% due to competition in the weight-loss medication market [10] - Marvell Technology Inc. gained 3.4% on the Nasdaq on December 24 [10] Commodity Markets - Gold and silver futures reached new all-time highs, with gold at $4,555 and silver at $72.75 per ounce [10] - WTI crude oil futures remained stable, trading near $58.40 per barrel [10]

Group 1 - The National Health Commission emphasizes the importance of flu vaccination as an effective preventive measure against influenza, particularly for vulnerable groups such as the elderly, children, and those with chronic illnesses [1] - Flu vaccination services are becoming more accessible, with many community health service centers offering convenient appointment options, encouraging higher vaccination rates for better community protection [1] - Common mild side effects of flu vaccination should not deter individuals from getting vaccinated, as the benefits outweigh the risks [1] Group 2 - Good hygiene practices are essential, including using tissues or elbows to cover coughs and sneezes, maintaining hand hygiene, and avoiding touching the face with unclean hands [2] - It is recommended to wash hands and change clothes upon returning home, especially after being in public, to minimize the risk of spreading infections [2] - Creating a fresh indoor environment through regular ventilation and cleaning, as well as disinfecting frequently touched surfaces, is crucial for health [2] Group 3 - Special precautions are advised for elderly individuals during rainy or snowy weather to prevent falls, including wearing non-slip shoes and walking slowly [3] - Outdoor workers, such as sanitation workers and delivery personnel, should take extra care to stay warm and protected from the cold, and are encouraged to get vaccinated against the flu [3] - Staying informed about weather forecasts and warnings is important for maintaining health and safety during winter [3]

Core Insights - Valneva SE announced positive final antibody persistence and safety data for its Phase 2 clinical trial of the chikungunya vaccine IXCHIQ, showing promising results in 304 children twelve months post-vaccination [1][2][3] Vaccine Efficacy and Safety - The full dose of IXCHIQ elicited a 94.7% seroresponse rate in chikungunya virus-naïve children at Day 360, indicating a strong immune response [3][4] - The vaccine was well tolerated across all age groups tested, with no safety concerns identified [3][4][9] - The trial results align with previous data reported in January and June 2025, confirming the robustness of the immune response and safety profile [2][5] Future Development Plans - The company plans to initiate a Phase 3 study in children after gathering additional real-world experience in the adolescent population, emphasizing the importance of safety [5][9] - The selection of the full dose for future trials is supported by the favorable immune response and safety data observed [4][9] Chikungunya Context - Chikungunya has seen a significant rise in cases globally, with Brazil reporting over one million cases from January 2019 to July 2024, highlighting the urgent need for effective vaccination [5][7] - The World Health Organization has identified chikungunya as a major public health problem, with the disease affecting over 110 countries since its re-emergence [6][7] Trial Details - The Phase 2 trial (VLA1553-221) was a multi-center, randomized, observer-blinded study involving 304 healthy children aged one to eleven years, conducted in the Dominican Republic and Honduras [8][10] - Participants were randomized to receive either a full dose, a half dose, or an active control, with the primary focus on evaluating safety and immunogenicity [8][10]